TW202019471A - 阿茲海默症之治療及預防方法 - Google Patents
阿茲海默症之治療及預防方法 Download PDFInfo
- Publication number
- TW202019471A TW202019471A TW108126224A TW108126224A TW202019471A TW 202019471 A TW202019471 A TW 202019471A TW 108126224 A TW108126224 A TW 108126224A TW 108126224 A TW108126224 A TW 108126224A TW 202019471 A TW202019471 A TW 202019471A
- Authority
- TW
- Taiwan
- Prior art keywords
- months
- individual
- composition
- administration
- relative
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US62/702,659 | 2018-07-24 | ||
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US62/749,614 | 2018-10-23 | ||
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US62/824,162 | 2019-03-26 | ||
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US62/846,902 | 2019-05-13 | ||
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| US62/874,684 | 2019-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202019471A true TW202019471A (zh) | 2020-06-01 |
Family
ID=67551415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108126224A TW202019471A (zh) | 2018-07-24 | 2019-07-24 | 阿茲海默症之治療及預防方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (https=) |
| EP (1) | EP3826674A2 (https=) |
| JP (2) | JP7541505B2 (https=) |
| KR (1) | KR20210039402A (https=) |
| CN (2) | CN118924896A (https=) |
| AU (1) | AU2019309938B2 (https=) |
| BR (1) | BR112021001272A2 (https=) |
| CA (1) | CA3107370A1 (https=) |
| IL (3) | IL280315B2 (https=) |
| MX (1) | MX2021000778A (https=) |
| PH (1) | PH12021500006A1 (https=) |
| TW (1) | TW202019471A (https=) |
| WO (1) | WO2020023530A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| RS67249B1 (sr) * | 2020-03-20 | 2025-10-31 | Eisai R&D Man Co Ltd | Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
| US20230302009A1 (en) * | 2020-08-12 | 2023-09-28 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| MX2024007288A (es) * | 2021-12-17 | 2024-06-28 | Eisai R&D Man Co Ltd | Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. |
| AU2022439338A1 (en) * | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| PL2233474T3 (pl) | 2008-01-18 | 2015-12-31 | Eisai R&D Man Co Ltd | Skondensowana pochodna aminodihydrotiazyny |
| LT2448968T (lt) | 2009-06-29 | 2021-05-10 | Bioarctic Ab | Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus |
| US20130084245A1 (en) * | 2010-02-25 | 2013-04-04 | Wyeth Llc | Pet monitoring of a-beta-directed immunotherapy |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| ES2624288T3 (es) | 2011-01-21 | 2017-07-13 | Eisai R&D Management Co., Ltd. | Métodos y compuestos útiles en la síntesis de derivados de aminodihidrotiazina condensados |
| WO2016005466A2 (en) * | 2014-07-10 | 2016-01-14 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| US20190016791A1 (en) * | 2016-01-20 | 2019-01-17 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| EP3454904B1 (en) * | 2016-05-13 | 2022-12-14 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| BR112019008359A2 (pt) * | 2016-10-27 | 2019-10-01 | Eisai R&D Man Co Ltd | método para tratamento da doença de alzheimer, e, composição farmacêutica. |
-
2019
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt active IP Right Grant
- 2019-07-23 IL IL310132A patent/IL310132B2/en unknown
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 AU AU2019309938A patent/AU2019309938B2/en active Active
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118924896A (zh) | 2024-11-12 |
| EP3826674A2 (en) | 2021-06-02 |
| WO2020023530A3 (en) | 2020-03-12 |
| MX2021000778A (es) | 2021-03-31 |
| IL280315B1 (en) | 2024-02-01 |
| CA3107370A1 (en) | 2020-01-30 |
| IL323583A (en) | 2025-11-01 |
| PH12021500006A1 (en) | 2021-09-13 |
| BR112021001272A2 (pt) | 2021-04-27 |
| CN112805031A (zh) | 2021-05-14 |
| IL280315B2 (en) | 2024-06-01 |
| JP7541505B2 (ja) | 2024-08-28 |
| IL310132B2 (en) | 2026-03-01 |
| US20210324056A1 (en) | 2021-10-21 |
| IL280315A (en) | 2021-03-25 |
| AU2019309938B2 (en) | 2026-04-02 |
| AU2019309938A1 (en) | 2021-03-11 |
| WO2020023530A2 (en) | 2020-01-30 |
| IL310132B1 (en) | 2025-11-01 |
| KR20210039402A (ko) | 2021-04-09 |
| JP2024112859A (ja) | 2024-08-21 |
| JP2021532126A (ja) | 2021-11-25 |
| IL310132A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202019471A (zh) | 阿茲海默症之治療及預防方法 | |
| US20250163135A1 (en) | Biomarkers for alzheimer's disease treatment | |
| JP2018111723A (ja) | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 | |
| JP2025506389A (ja) | ｐ－タウ１８１レベルを使用した治療方法 | |
| TWI894689B (zh) | 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途 | |
| CN117244056A (zh) | 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物 | |
| TW202430554A (zh) | 使用ｔａｕ ＰＥＴ水平之治療方法 | |
| TW202328178A (zh) | 抗Ａβ初原纖維抗體的皮下配製物及其使用方法 | |
| CN117940773A (zh) | 用于阿尔茨海默病治疗的生物标记物 | |
| RU2832167C2 (ru) | Способы лечения и предупреждения болезни альцгеймера | |
| HK40118843A (zh) | 阿尔茨海默病的治疗及预防方法 | |
| BR122025003268A2 (pt) | Métodos de tratamento e prevenção de doença de alzheimer | |
| CN118786141A (zh) | 使用p-tau181水平的治疗方法 | |
| TW202518027A (zh) | 抗微生物肽 | |
| WO2022251048A1 (en) | Anti-amyloid beta antibodies and uses thereof | |
| KR20260022396A (ko) | 항-Aβ 프로토피브릴 항체를 사용한 치료 방법 |